1 序文
2 範囲および方法論
2.1 本調査の目的
2.2 利害関係者
2.3 データソース
2.3.1 一次情報源
2.3.2 二次情報源
2.4 市場予測
2.4.1 ボトムアップアプローチ
2.4.2 トップダウンアプローチ
2.5 予測方法論
3 エグゼクティブサマリー
4 はじめに
4.1 概要
4.2 主要産業動向
5 世界の認知症治療薬市場
5.1 市場概要
5.2 市場実績
5.3 COVID-19 の影響
5.4 市場予測
6 疾患別の市場内訳
6.1 レビー小体型認知症
6.1.1 市場動向
6.1.2 市場予測
6.2 パーキンソン病性認知症
6.2.1 市場動向
6.2.2 市場予測
6.3 アルツハイマー病
6.3.1 市場動向
6.3.2 市場予測
6.4 血管性認知症
6.4.1 市場動向
6.4.2 市場予測
6.5 その他
6.5.1 市場動向
6.5.2 市場予測
7 薬効分類別市場
7.1 コリンエステラーゼ阻害剤
7.1.1 市場動向
7.1.2 市場予測
7.2 NMDA拮抗薬およびその配合薬
7.2.1 市場動向
7.2.2 市場予測
8 流通チャネル別市場規模推移
8.1 薬局
8.1.1 市場動向
8.1.2 市場予測
8.2 病院薬局
8.2.1 市場動向
8.2.2 市場予測
8.3 オンライン薬局
8.3.1 市場動向
8.3.2 市場予測
9 地域別市場
9.1 北米
9.1.1 米国
9.1.1.1 市場動向
9.1.1.2 市場予測
9.1.2 カナダ
9.1.2.1 市場動向
9.1.2.2 市場予測
9.2 アジア太平洋地域
9.2.1 中国
9.2.1.1 市場動向
9.2.1.2 市場予測
9.2.2 日本
9.2.2.1 市場動向
9.2.2.2 市場予測
9.2.3 インド
9.2.3.1 市場動向
9.2.3.2 市場予測
9.2.4 韓国
9.2.4.1 市場動向
9.2.4.2 市場予測
9.2.5 オーストラリア
9.2.5.1 市場動向
9.2.5.2 市場予測
9.2.6 インドネシア
9.2.6.1 市場動向
9.2.6.2 市場予測
9.2.7 その他
9.2.7.1 市場動向
9.2.7.2 市場予測
9.3 ヨーロッパ
9.3.1 ドイツ
9.3.1.1 市場動向
9.3.1.2 市場予測
9.3.2 フランス
9.3.2.1 市場動向
9.3.2.2 市場予測
9.3.3 英国
9.3.3.1 市場動向
9.3.3.2 市場予測
9.3.4 イタリア
9.3.4.1 市場動向
9.3.4.2 市場予測
9.3.5 スペイン
9.3.5.1 市場動向
9.3.5.2 市場予測
9.3.6 ロシア
9.3.6.1 市場動向
9.3.6.2 市場予測
9.3.7 その他
9.3.7.1 市場動向
9.3.7.2 市場予測
9.4 ラテンアメリカ
9.4.1 ブラジル
9.4.1.1 市場動向
9.4.1.2 市場予測
9.4.2 メキシコ
9.4.2.1 市場動向
9.4.2.2 市場予測
9.4.3 その他
9.4.3.1 市場動向
9.4.3.2 市場予測
9.5 中東およびアフリカ
9.5.1 市場動向
9.5.2 国別の市場内訳
9.5.3 市場予測
10 推進要因、阻害要因、機会
10.1 概要
10.2 推進要因
10.3 阻害要因
10.4 機会
11 バリューチェーン分析
12 ポーターのファイブフォース分析
12.1 概要
12.2 買い手の交渉力
12.3 売り手の交渉力
12.4 競争の度合い
12.5 新規参入の脅威
12.6 代替品の脅威
13 価格分析
14 競合状況
14.1 市場構造
14.2 主要企業
14.3 主要企業のプロフィール
Abbvie Inc
Apotex Inc
Biogen Inc
Eisai Co. Ltd
Johnson & Johnson
Merck & Co. Inc
Dementia Drugs Market Analysis:
Market Growth and Size: The global dementia drugs market is experiencing significant growth, driven by the increasing prevalence of dementia-related conditions, particularly Alzheimer's disease. Market size is expanding due to the aging global population and the rising demand for effective treatments to manage cognitive decline and improve the quality of life for patients.
Technological Advancements: Advances in neuroimaging technologies, biomarker identification, and precision medicine are aiding in early diagnosis and personalized treatment plans. Telemedicine and digital health platforms are enhancing remote monitoring and support for dementia patients and caregivers.
Industry Applications: The dementia drugs market is primarily focused on pharmaceuticals, including cholinesterase inhibitors and NMDA receptor antagonists. Non-pharmacological interventions, such as cognitive stimulation therapies and behavioral management strategies, are also gaining importance.
Geographical Trends: North America and Europe have well-established markets due to a higher prevalence of dementia and strong research infrastructure. Emerging markets in Asia-Pacific are experiencing rapid growth due to increasing awareness and healthcare investments.
Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. Pharmaceutical companies are also investing heavily in research and development to gain a competitive edge.
Challenges and Opportunities: Challenges include the high cost of drug development, regulatory hurdles, and the need for long-term clinical trials. Opportunities lie in early diagnosis, novel drug discovery, and non-pharmacological interventions.
Future Outlook: The dementia drugs market is poised for continued growth with a focus on disease-modifying therapies and personalized medicine. Advances in neuroimaging, biomarker identification, and telemedicine are expected to shape the future of dementia care.
Dementia Drugs Market Trends:
Ageing population
One of the primary drivers of the dementia drugs market is the aging global population. As people live longer, the incidence of age-related diseases like dementia naturally increases. This demographic shift results in a higher demand for dementia-related healthcare services and medications. The World Health Organization reports that the number of people aged 60 years and older is expected to double by 2050. This increase in the elderly population is likely to lead to a surge in the prevalence of dementia, thereby fueling the demand for effective dementia drugs.
Technological Advancements
The dementia drugs market is also driven by significant advancements in pharmaceutical research and development. With a better understanding of the neurobiological mechanisms behind dementia, pharmaceutical companies are increasingly investing in the development of more effective and targeted drugs. These advancements include the exploration of new therapeutic targets, such as amyloid plaques and tau proteins, which are believed to play a crucial role in the development of Alzheimer's disease, the most common form of dementia. Besides, advances in neuroimaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), enable more accurate diagnosis and monitoring of dementia-related conditions. Additionally, biomarker identification and genetic research are driving the development of precision medicine approaches. Technological innovations in drug discovery, clinical trial design, and telemedicine are also enhancing the efficiency of dementia drug development and patient care.
Increasing awareness and early diagnosis
There is a growing awareness about dementia and its symptoms, leading to earlier diagnosis and treatment. Public health campaigns and educational initiatives are increasing awareness of dementia's early signs, encouraging people to seek medical advice sooner. Early diagnosis is crucial in managing dementia effectively, as it allows for timely intervention and slows the progression of the disease. This growing awareness, coupled with improvements in diagnostic techniques, is driving the demand for dementia drugs.
Rising healthcare expenditure
Increasing healthcare expenditure globally is another factor boosting the dementia drugs market. Governments and healthcare organizations are allocating more resources to manage and treat chronic conditions, including dementia. This increased funding supports research, drug development, and improved access to treatment options. It also reflects a broader commitment to enhancing healthcare infrastructure and services, thereby facilitating better management of dementia symptoms and progression. Besides, governments, healthcare organizations, and advocacy groups are increasingly recognizing the urgency of addressing dementia. This recognition is driving funding for research and creating an environment conducive to pharmaceutical innovation.
Dementia Drugs Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on indication, drug class, and distribution channel.
Breakup by Indication:
Lewy Body Dementia
Parkinson’s Disease Dementia
Alzheimer’s Disease
Vascular Dementia
Others
Alzheimer’s disease accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the dementia drugs market based on the indication. This includes Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and others. According to the report, Alzheimer’s disease represented the largest segment.
Breakup by Drug Class:
Cholinesterase Inhibitors
NMDA Antagonists and its Combination Drugs
Cholinesterase inhibitors holds the largest share in the industry
A detailed breakup and analysis of the dementia drugs market based on the drug class has also been provided in the report. This includes cholinesterase inhibitors and NMDA antagonists and its combination drugs. According to the report, cholinesterase inhibitors accounted for the largest market share.
Breakup by Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Hospital pharmacies represents the leading market segment
The report has provided a detailed breakup and analysis of the dementia drugs market based on the distribution channel. This includes retail pharmacies, hospital pharmacies, and online pharmacies. According to the report, hospital pharmacies represented the largest segment.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest dementia drugs market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Abbvie Inc.
Apotex Inc.
Biogen Inc.
Eisai Co. Ltd.
Johnson & Johnson
Merck & Co. Inc.
Key Questions Answered in This Report:
How has the global dementia drugs market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global dementia drugs market?
What is the impact of each driver, restraint, and opportunity on the global dementia drugs market?
What are the key regional markets?
Which countries represent the most attractive dementia drugs market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the dementia drugs market?
What is the breakup of the market based on the drug class?
Which is the most attractive drug class in the dementia drugs market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the dementia drugs market?
What is the competitive structure of the market?
Who are the key players/companies in the global dementia drugs market?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Dementia Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Indication
6.1 Lewy Body Dementia
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Parkinson’s Disease Dementia
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Alzheimer’s Disease
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Vascular Dementia
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Drug Class
7.1 Cholinesterase Inhibitors
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 NMDA Antagonists and its Combination Drugs
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Retail Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Hospital Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbvie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Apotex Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Biogen Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eisai Co. Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Johnson & Johnson
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Merck & Co. Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
*** 認知症治療薬の世界市場に関するよくある質問(FAQ) ***
・認知症治療薬の世界市場規模は？
→IMARC社は2024年の認知症治療薬の世界市場規模を196億米ドルと推定しています。
・認知症治療薬の世界市場予測は？
→IMARC社は2033年の認知症治療薬の世界市場規模を357億米ドルと予測しています。
・認知症治療薬市場の成長率は？
→IMARC社は認知症治療薬の世界市場が2025年～2033年に年平均6.9%成長すると展望しています。
・世界の認知症治療薬市場における主要プレイヤーは？
→「Abbvie Inc., Apotex Inc., Biogen Inc., Eisai Co. Ltd., Johnson & Johnson, Merck & Co. Inc.など ...」を認知症治療薬市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
